Privat-docent thesis

Life cycle of a drug – a perspective for policy makers

Defense date2018

The interest in pharmaceutical agents is shared by key players pursuing the same general objective: to discover, test and treat patients. In this race, the pharmaceutical industries, regulatory bodies, physicians, patients, payers have various motivations, incentives and conflicting interests. As in most industrialised countries, Switzerland is expected to provide the best medicines to the largest number of patients using a limited budget, leaving the country struggling to reach a compromise between drug companies' profit maximization and authorities' cost containment issues. This thesis aims to describe the life cycle of a drug to give the reader a deeper knowledge of the key elements, different perspectives, and winning strategies that policy makers face when making highly valuable decisions.

  • Life cycle of a drug
  • Policy makers
  • Patent
  • Market access
  • Pricing models
  • Personal importation scheme
  • Evergreening stratégies
  • Spillover effect
Citation (ISO format)
VERNAZ-HEGI, Nathalie. Life cycle of a drug – a perspective for policy makers. 2018. doi: 10.13097/archive-ouverte/unige:106351
Main files (1)

Technical informations

Creation06/25/2018 2:18:00 PM
First validation06/25/2018 2:18:00 PM
Update time03/15/2023 8:24:26 AM
Status update03/15/2023 8:24:26 AM
Last indexation01/29/2024 9:32:30 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack